GBC AG Initiates Coverage on MustGrow Biologics Corp. with a BUY Rating

On July 7, 2026, GBC AG announced the initiation of coverage on MustGrow Biologics Corp., a Canadian firm innovating in agricultural biologicals derived from mustard. With a "BUY" rating and a target price set at CAD 2.70 / EUR 1.66, the review is based on the company's strategic market positioning in biological solutions.

MustGrow focuses on soil health and crop protection technologies. The company's flagship product, TerraSante, targets biofertility, while long-term prospects include TerraMG, a bio-crop protector. Collaboration with Bayer validates MustGrow's platform, enhancing its global reach potential.

GBC AG forecasts revenues rising from CAD 4.50 million in 2026 to CAD 31.56 million by 2028, driven by proprietary product scaling and margin improvement. Analysts highlight MustGrow's market differentiation leveraging quality and return on investment for growers beyond mere sustainability.